MSD Innovation Factory is looking for digital solutions for anaesthesiologists

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers. And that is the MSD Innovation Factory, where three out of the seven finalists (one per challenge) will get the top prize: up to $20,000 each to develop and locally launch the solution.

Co-create with a pharma and go together for unmet needs

MSD is having difficulty to reach anaesthesiologists to share the benefits of using Deep Block (DB) until the end of operations. Deep Block improves surgical conditions as it decreases the movement of the muscles and increases the volume at the operation area.

The main reason for not reaching them is their busy workload and the time spent at operation rooms, where MSD representatives cannot enter. There’s an opportunity for solutions oriented to education, e.g. while at the operating room, communication and team building with surgeons.

Worldwide participants are welcome to apply proposing solutions that will be implemented first in Turkey. The finalist of this challenge will have the opportunity to improve the proposal in collaboration with the local MSD team that proposed the challenge.

Find all the info about the anaesthesiologists challenge: https://www.msdinnovationfactory.com/challenges/anestouch/

Do you have a solution? Apply now!
www.msdinnovationfactory.com

How MSD Innovation Factory works

The innovation factory initiative aims to give support to the companies that come up with the best ideas to solve one of the 7 challenges identified in the EEMEA Region (Eastern Europe, Middle East and Africa) by local MSD teams.

The selection is done in four steps:

  • Solutions submitted before 31st October are reviewed by the challenge owners (the local MSD teams).
  • Each country will select the best solution for its proposed challenge.
  • During co-creation sessions the selected company and the local MSD team will work together in an improved proposal to be jointly presented in a Final event.
  • At the Final event in January 2018, the 7 finalists will pitch their solution in front of a senior jury from MSD. The jury will award 3 winners.

The prizes

Each of the 3 winners will receive the following:
  • Up to $20,000 to pilot their solution in the challenge-related local market.
  • Support from MSD local team to connect with the local ecosystem (eg. medical professional associations), deal with potential regulatory issues and disseminate leveraging MSD local channels. It will also contribute with expertise and business know-how.
  • If the local launch is a success after 12 months, its outcomes will be globally shared within MSD to investigate further implementation beyond the initial market.

All 7 finalists will get a 500€ grant to cover travel expenses to attend the Final event in Istanbul, and the opportunity to optimize their proposal in collaboration with the local MSD team that proposed the challenge. They will also receive visibility through the initiative communication channels.

MSD is a global healthcare company with a 125-year history committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

Applications until 31 October

Do you have a solution? Apply now!
www.msdinnovationfactory.com

Most Popular Now

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Pfizer and BioNTech announce data from preclinical…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based v...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Sinovac reports preliminary Phase I/II results of …

Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 vaccin...

CureVac expected to receive up to 252 million euro…

CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials...

COVID-19 study links strict social distancing to m…

Using public transportation, visiting a place of worship, or otherwise traveling from the home is associated with a significantly higher likelihood of testing positive wi...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...